{"analyses":[{"ciLowerLimit":"16.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"33.10","estimateComment":"The 95% CI was computed using Anderson-Hauck method.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.0001","paramType":"Difference in Response Rates","paramValue":"24.55","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"2.68","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"7.85","estimateComment":"OR was estimated using logistic regression model. The 95% CI was computed using Wald test.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"4.59"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55.37","upperLimit":"69.37","value":"62.6"},{"groupId":"OG001","lowerLimit":"81.57","upperLimit":"91.48","value":"87.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"194"}],"units":"Participants"}],"description":"Response was assessed by the IRC according to the iwCLL guidelines and was confirmed by repeat assessment \\>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \\<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, and constitutional symptoms; neutrophils \\>1500/mcL, platelets \\>100000/mcL, hemoglobin \\>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \\<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \\>/=50% reduction in two of the following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; and one of the following: neutrophils \\>1500/mcL, platelets \\>100000/mcL, hemoglobin \\>11.0 g/dL or \\>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. The 95% CI was computed using Pearson-Clopper method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received bendamustine at a dose of 70 milligrams per meter square (mg/m\\^2) via intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for 6 cycles, in combination with rituximab at a dose of 375 mg/m\\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\\^2 on Day 1 of Cycles 2-6.","id":"OG000","title":"Bendamustine + Rituximab Main Study"},{"description":"Participants were initially placed on a venetoclax ramp-up period of 5 weeks and received an initial dose of 20 mg via tablet orally once daily (QD) for initial 1 to 7 days, then venetoclax dose was incremented weekly up to a maximum dose of 400 mg, orally, QD. Participants continued receiving venetoclax at a dose of 400 mg, orally, QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to PD or 2 years, whichever occurred first, as directed by the investigator, in combination with rituximab at a dose of 375 mg/m\\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\\^2 on Day 1 of Cycles 2-6.","id":"OG001","title":"Venetoclax + Rituximab Main Study"}],"paramType":"NUMBER","populationDescription":"ITT population included all randomized participants, with participants grouped according to randomized treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"EoCTR visit (8 to 12 weeks after C6D1); Cycle length = 28 days","title":"Percentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the IRC Using iwCLL Guidelines","type":"SECONDARY","unitOfMeasure":"percentage of participants"}